Terms: = Breast cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1 AND Clinical Outcome
37 results:
1. Flexible Etherified and Esterified Triphenylethylene Derivatives and Their Evaluation on ER-positive and Triple-Negative breast cancer Cell Lines.
Hassan AS; Wober J; Vollmer G; Abadi AH; Ahmed NS
ChemMedChem; 2022 Apr; 17(7):e202100720. PubMed ID: 35076180
[TBL] [Abstract] [Full Text] [Related]
2. Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse.
Sanchez-Spitman AB; Swen JJ; Dezentjé VO; Moes DJAR; Gelderblom H; Guchelaar HJ
Sci Rep; 2021 Jan; 11(1):415. PubMed ID: 33432065
[TBL] [Abstract] [Full Text] [Related]
3. Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics.
Slanař O; Hronová K; Bartošová O; Šíma M
Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):307-321. PubMed ID: 33320718
[No Abstract] [Full Text] [Related]
4. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
[TBL] [Abstract] [Full Text] [Related]
5.
Tamura K; Imamura CK; Takano T; Saji S; Yamanaka T; Yonemori K; Takahashi M; Tsurutani J; Nishimura R; Sato K; Kitani A; Ueno NT; Mushiroda T; Kubo M; Fujiwara Y; Tanigawara Y
J Clin Oncol; 2020 Feb; 38(6):558-566. PubMed ID: 31821071
[TBL] [Abstract] [Full Text] [Related]
6. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
[TBL] [Abstract] [Full Text] [Related]
7. Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.
Sanchez-Spitman AB; Dezentjé VO; Swen JJ; Moes DJAR; Gelderblom H; Guchelaar HJ
Breast Cancer Res Treat; 2018 Nov; 172(2):401-411. PubMed ID: 30120701
[TBL] [Abstract] [Full Text] [Related]
8. Effect of CYP2C19 and cyp2d6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.
Sim S; Lövrot J; Lindh JD; Bergh J; Xie H
Pharmacogenomics; 2018 Aug; 19(13):1027-1037. PubMed ID: 30022682
[TBL] [Abstract] [Full Text] [Related]
9. cyp2d6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.
Hertz DL; Kidwell KM; Hilsenbeck SG; Oesterreich S; Osborne CK; Philips S; Chenault C; Hartmaier RJ; Skaar TC; Sikora MJ; Rae JM
Breast Cancer Res Treat; 2017 Nov; 166(1):277-287. PubMed ID: 28730340
[TBL] [Abstract] [Full Text] [Related]
10. [Advances in the research of pharmacogenomics of tamoxifen].
Xiong W; Zhao JJ; Wang L; Jiang XH; Tao XQ
Yao Xue Xue Bao; 2016 Sep; 51(9):1356-67. PubMed ID: 29924509
[TBL] [Abstract] [Full Text] [Related]
11. cyp2d6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian breast cancer Patients.
Chin FW; Chan SC; Abdul Rahman S; Noor Akmal S; Rosli R
Breast J; 2016; 22(1):54-62. PubMed ID: 26510986
[TBL] [Abstract] [Full Text] [Related]
12. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes.
Watanabe M; Watanabe N; Maruyama S; Kawashiro T
Drug Metab Pharmacokinet; 2015 Oct; 30(5):325-33. PubMed ID: 26423799
[TBL] [Abstract] [Full Text] [Related]
13. RRM1, TUBB3, TOP2A, CYP19A1, cyp2d6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
[TBL] [Abstract] [Full Text] [Related]
14. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
Zembutsu H
Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
[TBL] [Abstract] [Full Text] [Related]
15. Individualization of tamoxifen therapy: much more than just cyp2d6 genotyping.
Binkhorst L; Mathijssen RH; Jager A; van Gelder T
Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
[TBL] [Abstract] [Full Text] [Related]
16. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.
Saladores P; Mürdter T; Eccles D; Chowbay B; Zgheib NK; Winter S; Ganchev B; Eccles B; Gerty S; Tfayli A; Lim JS; Yap YS; Ng RC; Wong NS; Dent R; Habbal MZ; Schaeffeler E; Eichelbaum M; Schroth W; Schwab M; Brauch H
Pharmacogenomics J; 2015 Feb; 15(1):84-94. PubMed ID: 25091503
[TBL] [Abstract] [Full Text] [Related]
17. Population pharmacokinetic modelling to assess the impact of cyp2d6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
ter Heine R; Binkhorst L; de Graan AJ; de Bruijn P; Beijnen JH; Mathijssen RH; Huitema AD
Br J Clin Pharmacol; 2014 Sep; 78(3):572-86. PubMed ID: 24697814
[TBL] [Abstract] [Full Text] [Related]
18. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and cyp2d6 studies.
Kiyotani K; Mushiroda T; Zembutsu H; Nakamura Y
J Hum Genet; 2013 Jun; 58(6):327-33. PubMed ID: 23657426
[TBL] [Abstract] [Full Text] [Related]
19. The use of the 13C-dextromethorphan breath test for phenotyping cyp2d6 in breast cancer patients using tamoxifen: association with cyp2d6 genotype and serum endoxifen levels.
Opdam FL; Dezentje VO; den Hartigh J; Modak AS; Vree R; Batman E; Smorenburg CH; Nortier JW; Gelderblom H; Guchelaar HJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):593-601. PubMed ID: 23228987
[TBL] [Abstract] [Full Text] [Related]
20. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters.
Kiyotani K; Mushiroda T; Nakamura Y; Zembutsu H
Drug Metab Pharmacokinet; 2012; 27(1):122-31. PubMed ID: 22041137
[TBL] [Abstract] [Full Text] [Related]
[Next]
